Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CELC |
---|---|---|
09:32 ET | 860 | 15.14 |
09:34 ET | 326 | 15.13 |
09:36 ET | 100 | 15.27 |
09:38 ET | 100 | 15.26 |
09:39 ET | 100 | 15.25 |
09:41 ET | 200 | 15.24 |
09:43 ET | 706 | 15.2 |
09:45 ET | 100 | 15.18 |
09:48 ET | 100 | 15.26 |
09:52 ET | 100 | 15.27 |
09:54 ET | 320 | 15.28 |
09:59 ET | 100 | 15.205 |
10:01 ET | 200 | 15.12 |
10:06 ET | 200 | 15.075 |
10:12 ET | 300 | 15.06 |
10:15 ET | 3159 | 15.25 |
10:17 ET | 700 | 15.22 |
10:19 ET | 100 | 15.27 |
10:21 ET | 100 | 15.34 |
10:24 ET | 300 | 15.21 |
10:26 ET | 100 | 15.255 |
10:32 ET | 100 | 15.22 |
10:33 ET | 500 | 15.255 |
10:35 ET | 2240 | 15.125 |
10:37 ET | 100 | 15.12 |
10:39 ET | 276 | 15.01 |
10:42 ET | 900 | 15.145 |
10:44 ET | 100 | 15.209 |
10:48 ET | 100 | 15.21 |
10:50 ET | 300 | 15.13 |
10:51 ET | 100 | 15.17 |
10:53 ET | 300 | 15.17 |
10:55 ET | 100 | 15.16 |
10:57 ET | 500 | 15.18 |
11:04 ET | 100 | 15.19 |
11:06 ET | 100 | 15.18 |
11:08 ET | 400 | 15.19 |
11:13 ET | 900 | 15.13 |
11:20 ET | 200 | 15.16 |
11:22 ET | 200 | 15.08 |
11:24 ET | 200 | 15.105 |
11:26 ET | 300 | 15.14 |
11:27 ET | 300 | 15.155 |
11:29 ET | 750 | 15.13 |
11:31 ET | 500 | 15.17 |
11:36 ET | 400 | 15.18 |
11:38 ET | 100 | 15.15 |
11:40 ET | 300 | 15.16 |
11:42 ET | 200 | 15.09 |
11:44 ET | 501 | 15.09 |
11:47 ET | 200 | 15.02 |
11:49 ET | 100 | 15.03 |
11:54 ET | 600 | 15.055 |
11:56 ET | 200 | 15.03 |
12:00 ET | 109 | 15.02 |
12:03 ET | 200 | 15.03 |
12:07 ET | 100 | 15.06 |
12:18 ET | 800 | 15.13 |
12:20 ET | 1097 | 15.135 |
12:23 ET | 400 | 15.08 |
12:25 ET | 100 | 15.05 |
12:32 ET | 200 | 15.075 |
12:34 ET | 501 | 15.03 |
12:39 ET | 200 | 15.05 |
12:41 ET | 100 | 15 |
12:43 ET | 100 | 15.04 |
12:48 ET | 200 | 15.015 |
12:54 ET | 200 | 15.01 |
12:59 ET | 800 | 15.03 |
01:03 ET | 552 | 15.07 |
01:12 ET | 100 | 15.07 |
01:15 ET | 100 | 15.1 |
01:17 ET | 500 | 15.1 |
01:19 ET | 100 | 15.15 |
01:24 ET | 100 | 15.155 |
01:28 ET | 600 | 15.14 |
01:30 ET | 100 | 15.18 |
01:32 ET | 200 | 15.16 |
01:33 ET | 100 | 15.16 |
01:37 ET | 900 | 15.15 |
01:42 ET | 1363 | 15.225 |
01:44 ET | 100 | 15.225 |
01:48 ET | 1100 | 15.195 |
01:53 ET | 400 | 15.18 |
01:57 ET | 1625 | 15.15 |
02:00 ET | 1100 | 15.15 |
02:02 ET | 100 | 15.12 |
02:04 ET | 100 | 15.145 |
02:06 ET | 600 | 15.12 |
02:08 ET | 600 | 15.135 |
02:11 ET | 300 | 15.12 |
02:18 ET | 649 | 15.13 |
02:20 ET | 200 | 15.1 |
02:22 ET | 200 | 15.1 |
02:24 ET | 646 | 15.12 |
02:26 ET | 100 | 15.1 |
02:27 ET | 700 | 15.13 |
02:31 ET | 806 | 15.195 |
02:33 ET | 600 | 15.1 |
02:38 ET | 965 | 15.1065 |
02:40 ET | 300 | 15.125 |
02:42 ET | 100 | 15.11 |
02:44 ET | 400 | 15.1 |
02:45 ET | 700 | 15.065 |
02:47 ET | 400 | 15.05 |
02:49 ET | 600 | 15.11 |
02:51 ET | 300 | 15.115 |
02:56 ET | 100 | 15.115 |
02:58 ET | 200 | 15.14 |
03:00 ET | 100 | 15.09 |
03:02 ET | 900 | 15.165 |
03:03 ET | 200 | 15.2 |
03:05 ET | 400 | 15.18 |
03:07 ET | 600 | 15.17 |
03:09 ET | 300 | 15.14 |
03:12 ET | 550 | 15.07 |
03:14 ET | 600 | 15.08 |
03:16 ET | 300 | 15.12 |
03:18 ET | 500 | 15.08 |
03:20 ET | 100 | 15.09 |
03:21 ET | 821 | 15.07 |
03:23 ET | 723 | 15.13 |
03:27 ET | 600 | 15.15 |
03:30 ET | 1200 | 15.185 |
03:32 ET | 1100 | 15.2 |
03:34 ET | 1000 | 15.19 |
03:36 ET | 2521 | 15.225 |
03:38 ET | 1300 | 15.09 |
03:41 ET | 500 | 15.08 |
03:43 ET | 1750 | 15.01 |
03:45 ET | 600 | 15.02 |
03:48 ET | 650 | 15.03 |
03:52 ET | 900 | 15.03 |
03:54 ET | 3442 | 15.02 |
03:56 ET | 528 | 15.03 |
03:57 ET | 2125 | 15 |
03:59 ET | 19480 | 15.03 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Celcuity Inc | 527.6M | -5.4x | --- |
Terns Pharmaceuticals Inc | 530.4M | -6.5x | --- |
Corbus Pharmaceuticals Holdings Inc | 535.4M | -7.2x | --- |
Erasca Inc | 516.4M | -2.6x | --- |
Cabaletta Bio Inc | 514.6M | -6.2x | --- |
Replimune Group Inc | 513.7M | -2.6x | --- |
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its initial clinical development programs for gedatolisib are focusing on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $527.6M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 35.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.80 |
EPS | $-2.79 |
Book Value | $5.48 |
P/E Ratio | -5.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.